A pharmaceutical composition is provided comprising a first agent in an amount effective for causing both a peripheral effect and a central effect on weight loss, a second agent in an amount effective for causing at least a central effect on weight loss, and one or more pharmaceutically acceptable excipients, wherein the first agent and the second agent are different. Also provided are a method of causing weight loss and a method of preventing or treating cachexia syndrome.

A method of treating a disease or disorder that can benefit from increasing an M2/M1 macrophage ratio in a subject in need thereof is provided. The method comprising: (a) culturing basophils in the presence of IL33 and/or GM-SCF; and (b) administering to the subject a therapeutically effective amount of the basophils following the culturing, thereby treating the disease or disorder that can benefit from increasing an M2/M1 macrophage ratio in the subject.

Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.

The present invention relates to compositions and methods variously useful in treating cancer, inhibiting graft rejection, and treating autoimmune disease. The compositions and methods include those in which macrophages are conditioned to down regulate or upregulate the expression or activity of SIRPα or its interaction with CD47.

Methods for making and using pain mediator compositions are described herein. These pain mediator compositions can be used to discover and develop pain therapeutics and to evaluate test compounds for their effect on pain associated with a particular disease or condition.

The present application provides bio-mimetic formulations, including formulations that mimic mammalian amniotic membrane and/or fluid, but with optimized amounts and formulas of various recombinant peptides. These formulations are stable for extended periods and can be used in various treatment methods including wound healing.

The described invention provides a method of treating a lung injury at risk of progressing to a fibrotic lung disease in a subject in need thereof comprising administering to the subject a composition comprising a therapeutic amount of IL-6 polypeptide, hyaluronan (HA), mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof, wherein the therapeutic amount is effective to increase renewal of alveolar epithelial cell 2 (AEC2) stem cells, to repair the injury, to reduce lung fibrosis, or a combination thereof.

Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.

According to a skin ointment for treating labia minora skin according to the present disclosure, the skin ointment includes multi-growth factors as active ingredients, and is periodically applied to the vulva of a user so that the growth factors induce the regeneration of skin cells of the user, thereby increasing the effect of treating vulvar vestibulitis or wounds due to labia minora surgery, and addressing the fundamental causes thereof.

The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.